The University of Tokyo Hospital announced on Friday that it has begun clinical trials of the combined use of two medications, the new influenza drug Avigan and a drug for treating acute pancreatitis Futhan, in the treatment of patients with pneumonia caused by the new strain of coronavirus.
A team from the university's Institute of Medical Science has already found that Futhan can possibly prevent the new coronavirus from entering human cells, while Avigan is believed to prevent virus growth inside cells. The clinical research is conducted on patients ranging from 20 to 74 years old that have been admitted to six hospitals, including The University of Tokyo Hospital. By comparing patients who receive the combination of medications and those who receive only Avigan, the team will verify any differences in effectivity and safety between the two groups.
Read more from The Japan News at https://japannews.yomiuri.co.jp/
